These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 18788407)

  • 41. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of statins on renal function.
    Agarwal R
    Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
    Baber U; Toto RD; de Lemos JA
    Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dyslipidemia of kidney disease.
    Attman PO; Samuelsson O
    Curr Opin Lipidol; 2009 Aug; 20(4):293-9. PubMed ID: 19512921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dyslipidemia and the risk of end stage renal disease.
    Haydar AA; Goldsmith DJ
    J Med Liban; 2004; 52(3):156-9. PubMed ID: 16432973
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diminished glomerular filtration rate as a marker of chronic kidney disease in hypertensive patients].
    Grabysa R; Cholewa M
    Pol Merkur Lekarski; 2008 Jun; 24(144):487-91. PubMed ID: 18702327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
    Minami J; Ishimitsu T; Sudo Y; Matsuoka H
    Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?
    Conley J; Olafsson A; Djamali A
    J Nephrol; 2010; 23(3):321-7. PubMed ID: 20301084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Progression factors for chronic kidney disease. Secondary prevention].
    García de Vinuesa S
    Nefrologia; 2008; 28 Suppl 3():17-21. PubMed ID: 19018733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dyslipidemia in chronic kidney disease: managing a high-risk combination.
    Chauhan V; Vaid M
    Postgrad Med; 2009 Nov; 121(6):54-61. PubMed ID: 19940417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of cardiovascular disease in chronic kidney disease patients.
    Wanner C
    Semin Nephrol; 2009 Jan; 29(1):24-9. PubMed ID: 19121471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease.
    McCullough PA; Verrill TA
    Postgrad Med; 2010 Mar; 122(2):25-34. PubMed ID: 20203453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid changes and statins in chronic renal insufficiency and dialysis.
    Wanner C; Krane V; Metzger T; Quaschning T
    J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Statins in chronic renal disease].
    Ferreira SR; Rocha AM; Saraiva JF
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.